Haller G W, Bechstein W O, Neuhaus R, Raakow R, Berg T, Hopf U, Neuhaus P
Department of Surgery, Virchow Clinic, Humboldt University of Berlin, Germany.
Transpl Int. 1996;9 Suppl 1:S210-2. doi: 10.1007/978-3-662-00818-8_53.
Between November 1993 and June 1995 18 patients received oral famciclovir (3 x 500 mg) for treatment of hepatitis B virus (HBV) reinfection after liver transplantation. Reinfection was defined as the reoccurrence of HBsAg in the serum. In the first 15 patients, famciclovir therapy was initiated after clinical signs of graft hepatitis, whereas the last 3 patients received treatment immediately after HBV-DNA was detected. Famciclovir was well-tolerated in all patients. HBV-DNA values were decreased to undetectable levels in 8 out of 18 patients. Clinical status improved in 7 patients, whereas 5 patients remained unchanged and 6 patients progressed to deteriorating graft function and death. When famciclovir was initiated early after reinfection, a response rate of approximately 66% was observed. Late onset of therapy in patients with fulminant hepatitis generally failed to provide any clinical benefit.
1993年11月至1995年6月期间，18例患者接受口服泛昔洛韦（3×500毫克）治疗肝移植后乙肝病毒（HBV）再感染。再感染定义为血清中HBsAg再次出现。前15例患者在出现移植肝肝炎临床症状后开始使用泛昔洛韦治疗，而最后3例患者在检测到HBV-DNA后立即接受治疗。所有患者对泛昔洛韦耐受性良好。18例患者中有8例HBV-DNA值降至检测不到的水平。7例患者临床状况改善，5例患者病情未变，6例患者移植肝功能恶化并死亡。再感染后早期开始使用泛昔洛韦时，观察到的有效率约为66%。暴发性肝炎患者治疗开始较晚通常未能带来任何临床益处。
